SAN DIEGO (AP) -- Diabetes drug maker Amylin Pharmaceuticals Inc. said Thursday that sales of its new drug Bydureon totaled $6.9 million in the first quarter, missing analysts' estimates. Amylin took ...

PHILADELPHIA-- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Alkermes plc (Nasdaq: ALKS) today announced results from an analysis of seven randomized clinical studies demonstrating that patients ...

Bydureon BCise was discontinued by its manufacturer AstraZeneca on October 28, 2024. This drug is no longer available in the United States. Discontinuation of Bydureon BCise was a business decision by ...

PHILADELPHIA-- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Alkermes plc (Nasdaq: ALKS) today announced clinical study results which showed that a significantly greater proportion of patients ...

First and Only Once-Weekly Type 2 Diabetes Medication Delivers Powerful Glycemic Control in a Single Dose INDIANAPOLIS, SAN DIEGO and WALTHAM, Mass., June 21, 2011 /PRNewswire/ -- Eli Lilly and ...

BYDUREON works with the body to help make its own insulin when needed, providing continuous glycemic control with just one dose per week. Using Alkermes’ proprietary technology for long-acting ...

Bydureon BCise was discontinued by its manufacturer AstraZeneca on October 28, 2024. This drug is no longer available in the United States. Discontinuation of Bydureon BCise was a business decision by ...

As pundits continue to ponder the unanswered questions surrounding Amylin Pharmaceuticals and its rejection of a bid by Bristol-Myers Squibb – did the big drugmaker really make a bid? if so, when? and ...

AstraZeneca plc AZN announced top-line results from the EXSCEL study evaluating the cardiovascular (CV) safety profile of its type II diabetes drug Bydureon. Though the study met the primary safety ...

AstraZeneca has had a setback to its ambitions in diabetes, after Bydureon failed to show cardiovascular benefits to patients. The FDA now obliges companies with diabetes products to conduct large ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...